Osaka, Jan. 20 (Jiji Press)–Japanese pharmaceutical company Shionogi & Co. said Tuesday that it will spend 2,125 million dollars to raise its stake in British HIV drugs company ViiV Healthcare Ltd. from 10 pct to 21.7 pct. ViiV will issue new shares to Shionogi for the additional investment. Procedures are expected to be completed by the end of March. ViiV will cancel the 11.7 pct stake in the company held by U.S. pharmaceutical giant Pfizer Inc., a deal that will keep the stake in ViiV held by British pharmaceutical company GSK plc unchanged at 78.3 pct. “We are delighted to further deepen our strategic partnership with GSK and ViiV through this agreement, redoubling our commitment and participation in improving the lives of people living with or affected by HIV,” John Keller, senior executive officer at Shionogi, said in a statement. Shionogi has been in collaboration with GSK in the field of HIV drugs since 2001. END [Copyright The Jiji Press, Ltd.]
Shionogi to Raise Stake in British HIV Drugs Firm ViiV
Related Posts
Honda Expects Up to 690 B. Yen in Net Loss for FY 2025
Tokyo, March 12 (Jiji Press)–Japan’s Honda Motor Co. said Thursday that it expects to post a consolidated net loss of 420 billion to 690 billion yen in fiscal 2025 ending this month. The automaker revised down its estimate from a net profit
48 Pct of Japanese Oppose Exporting Lethal Weapons: Jiji Poll
Tokyo, March 12 (Jiji Press)–Nearly half of Japanese people oppose lifting their country’s export ban on lethal weapons, a Jiji Press public opinion poll showed Thursday. In the March survey, 48.2 pct of respondents rejected the ruling coalition’s proposal to allow exports
